BUSILVEX (busulfan)

Conditioning treatment prior to conventional haematopoietic stem cell transplantation:

- No clinical benefit demonstrated in adults compared to other available conditioning regimens.

- Minor clinical benefit in infants, children and adolescents compared to total body irradiation.

• BUSILVEX has Marketing Authorisation in 3 indications for conditioning treatment prior to conventional haematopoietic stem cell (HSC) transplantation:

      - BUSILVEX followed by cyclophosphamide in adults,

      - BUSILVEX followed by cyclophosphamide or melphalan in infants, children and adolescents,

     - BUSILVEX administered after fludarabine in adults eligible for a reduced intensity conditioning (RIC).

• New data confirm that busulfan IV-based regimens are an effective therapeutic strategy in the myeloablative conditioning treatment of infants, children and adolescents and adults, as well as in reduced intensity conditioning in adults.

• Busulfan IV-based conditioning regimens prior to HSC transplantation are first-line treatments.